| Crohn Disease
Skyrizi vs Humira
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Skyrizi vs Humira with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHumira has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Humira but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Humira
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
SC injection
Every other week
TNF-alpha antagonist
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Chronic small plaque psoriasis
- Hidradenitis Suppurativa
- Uveitis
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.
Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).
Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
—
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.
Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Humira
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humira
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Humira
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Humira Complete Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
HumiraView full Humira profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.